1. Home
  2. AKBA vs STAA Comparison

AKBA vs STAA Comparison

Compare AKBA & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • STAA
  • Stock Information
  • Founded
  • AKBA 2007
  • STAA 1982
  • Country
  • AKBA United States
  • STAA United States
  • Employees
  • AKBA N/A
  • STAA N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • STAA Ophthalmic Goods
  • Sector
  • AKBA Health Care
  • STAA Health Care
  • Exchange
  • AKBA Nasdaq
  • STAA Nasdaq
  • Market Cap
  • AKBA 958.6M
  • STAA 850.4M
  • IPO Year
  • AKBA 2014
  • STAA N/A
  • Fundamental
  • Price
  • AKBA $3.69
  • STAA $16.74
  • Analyst Decision
  • AKBA Strong Buy
  • STAA Hold
  • Analyst Count
  • AKBA 5
  • STAA 8
  • Target Price
  • AKBA $6.90
  • STAA $27.17
  • AVG Volume (30 Days)
  • AKBA 6.6M
  • STAA 844.7K
  • Earning Date
  • AKBA 08-07-2025
  • STAA 08-06-2025
  • Dividend Yield
  • AKBA N/A
  • STAA N/A
  • EPS Growth
  • AKBA N/A
  • STAA N/A
  • EPS
  • AKBA N/A
  • STAA N/A
  • Revenue
  • AKBA $184,909,000.00
  • STAA $279,134,000.00
  • Revenue This Year
  • AKBA $26.88
  • STAA N/A
  • Revenue Next Year
  • AKBA $44.34
  • STAA $29.34
  • P/E Ratio
  • AKBA N/A
  • STAA N/A
  • Revenue Growth
  • AKBA N/A
  • STAA N/A
  • 52 Week Low
  • AKBA $0.80
  • STAA $13.50
  • 52 Week High
  • AKBA $4.08
  • STAA $49.86
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 63.96
  • STAA 45.12
  • Support Level
  • AKBA $3.56
  • STAA $16.19
  • Resistance Level
  • AKBA $3.87
  • STAA $17.29
  • Average True Range (ATR)
  • AKBA 0.22
  • STAA 0.71
  • MACD
  • AKBA -0.04
  • STAA -0.02
  • Stochastic Oscillator
  • AKBA 36.53
  • STAA 28.51

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

Share on Social Networks: